L4 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2003 ACS on STN
AN 2001:31508 CAPLUS
DN 134:95528
TI Potassium channel blocking agents
IN Teuber, Lene; Olesen, Soren Peter; Strobaek, Dorte
PA Neurosearch A/S, Den.
SO PCT Int. Appl., 38 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001002406	A1	20010111	WO 2000-DK332	20000622
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	EP 1196419	A1	20020417	EP 2000-938583	20000622
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
	JP 2003503501	T2	20030128	JP 2001-507842	20000622
	US 2002128279	A1	20020912	US 2001-29168	20011228
PRAI	DK 1999-927	A	19990629		
	WO 2000-DK332	W	20000622		

OS MARPAT 134:95528
AB This invention relates to novel potassium channel blocking agents, and their use in the prepn. of pharmaceutical compns. Moreover the invention is directed to pharmaceutical compns. useful for the treatment or alleviation of diseases or disorders assocd. with the activity of potassium channels, in particular asthma, cystic fibrosis, chronic obstructive pulmonary disease and rhinorrhea, convulsions, vascular spasms, coronary artery spasms, renal disorders, polycystic kidney disease, bladder spasms, urinary incontinence, bladder outflow obstruction, irritable bowel syndrome, gastrointestinal dysfunction, secretory diarrhea, ischemia, cerebral ischemia, ischemic heart disease, angina pectoris, coronary heart disease, traumatic brain injury, psychosis, anxiety, depression, dementia, memory and attention deficits, Alzheimer's disease, dysmenorrhea, narcolepsy, Reynaud's disease, intermittent claudication, Sjogren's syndrome, migraine, arrhythmia, hypertension, absence seizures, myotonic muscle dystrophy, xerostomia, diabetes type II, hyperinsulinemia, premature labor, baldness, cancer, and immune suppression.
IT **318499-96-6P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)(potassium channel blocking agents for the prepn. of pharmaceutical compns. for disease treatment)
RN 318499-96-6 CAPLUS
CN 8,12-Methano-5,26:15,21-dinitrilo-6H-dibenzo[i,v][1,3,6,8,12,20]hexaazacyclotricosine,

7,8,9,10,11,12,13,14,22,23,24,25-dodecahydro-22,25-dimethyl-
(9CI) (CA INDEX NAME)



RE.CNT 9 THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2003 ACS on STN
AN 1989:17693 CAPLUS
DN 110:17693
TI A new macrocyclic ligand combining two different coordination sites: macrocyclic biquinazoline (Mabiq-). Synthesis and structure of the free ligand and of a cobalt(III) complex
AU Mueller, Edgar; Bernardinelli, Gerald; Von Zelewsky, Alex
CS Dep. Chim. Miner., Anal. Appl., Univ. Geneva, Geneva, 1211, Switz.
SO Inorganic Chemistry (1988), 27(25), 4645-51
CODEN: INOCAJ; ISSN: 0020-1669
DT Journal
LA English
GI



I

AB The prepn. of I (HMabiq), combining a corrin type macrocyclic environment with an addnl. diimine type coordination site, is described. The yellow compd. crystallizes in the orthorhombic system (P212121) with a 10.831(2), b 12.201(2), c 21.978(4) .ANG., and Z = 4. [Co(Mabiq)(CN)2] crystallizes in the triclinic system (P1) with a 10.211(1), b 18.785(3), c 19.262(3) .ANG., .alpha. 107.80(1), .beta. 100.14(2), .gamma. 98.96(2).degree., and Z = 4. This compd. is a model for dicyanocobalamine, as seen from its narrow UV/visible absorption peak at 536 nm (.epsilon. = 19,000) and the reversible CoII/CoI redn.-oxidn. wave at -0.41 V (NHE).

IT **117709-42-9P**
RL: PRP (Properties); SPN (Synthetic preparation); PREP (Preparation)
(prepn. and crystal structure of)

RN 117709-42-9 CAPLUS
CN 5,24-Imino-10,7:15,12:17,23-trinitrilo-7H-dibenzo[e,t][1,4,8,18]tetraazacycloheneicosine, 8,9,13,14-tetrahydro-8,8,9,9,13,13,14,14-octamethyl- (9CI)(CA INDEX NAME)



=> d l1; d his; log y
L1 HAS NO ANSWERS
L1 STR





Structure attributes must be viewed using STN Express query preparation.

(FILE 'HOME' ENTERED AT 18:20:55 ON 22 AUG 2003)

FILE 'REGISTRY' ENTERED AT 18:21:03 ON 22 AUG 2003
L1 STRUCTURE UPLOADED
L2 0 S L1
L3 3 S L1 FUL

FILE 'CAPLUS' ENTERED AT 18:21:28 ON 22 AUG 2003
L4 2 S L3

FILE 'BEILSTEIN' ENTERED AT 18:22:02 ON 22 AUG 2003
L5 0 S L1
L6 0 S L1 FUL

FILE 'MARPAT' ENTERED AT 18:22:17 ON 22 AUG 2003
L7 0 S L1
L8 1 S L1 FUL
L9 0 S L8 NOT L4

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	104.55	262.46

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	0.00	-1.30

STN INTERNATIONAL LOGOFF AT 18:22:44 ON 22 AUG 2003